Roche spins out Nim­ble Ther­a­peu­tics to cap­i­tal­ize on pep­tide drug dis­cov­ery, with $10M sup­port from Tele­graph Hill Part­ners

In 2007, Roche Di­ag­nos­tics ac­quired Madi­son, Wis­con­sin-based Nim­ble­Gen as it looked to add DNA mi­croar­ray tech to its ge­nomics re­search toolk­it. The phar­ma gi­ant has since shut­tered the unit, laid off staffers and an­nounced it would close the site al­to­geth­er, but the tech­nol­o­gy is liv­ing on as a drug dis­cov­ery plat­form in a new spin­out.

Im­age: Ji­gar Pa­tel NIM­BLE

Nim­ble Ther­a­peu­tics has se­cured a Se­ries A from San Fran­cis­co’s Tele­graph Hill Part­ners to be­gin court­ing phar­ma com­pa­nies that might be in­ter­est­ed in ap­ply­ing their “mas­sive­ly par­al­lel chem­i­cal syn­the­sis” to gen­er­ate and screen pep­tide-based ther­a­pies. They have $10 mil­lion to get start­ed, an SEC fil­ing re­vealed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER